RD Congo - Ituri et Nord-Kivu : Suivi des Indicateurs Clés de Performance de la riposte à la Maladie à Virus Ebola (Semaine 44 : du 28 octobre au 03 novembre 2019) - Democratic Republic of the Congo - ReliefWeb

-

Informing humanitarians worldwide.

A service provided by UN OCHA

ReliefWeb has been the leading online source for reliable and timely humanitarian information on global crises and disasters since 1996.
Learn more about ReliefWeb



https://ift.tt/36QEiWV

Comments

Post a Comment

Popular posts from this blog

Ebola has spread for nearly a year in Congo. Officials are scrambling to ‘reset’ the response. - The Washington Post

-
Image
June 20 at 4:06 PM BUTEMBO, Congo —  A dozen young men revved their motor­cycle engines in front of the wooden gate of a makeshift checkpoint — too impatient to have their temperatures checked or to wash their hands with chlorinated water. Health workers manning the post had little choice but to let them pass. Every day, thousands of people travel this road through the epicenter of Congo’s ongoing Ebola outbreak, where they are supposed to comply with field nurses toting gun-shaped thermometers testing for fevers. But that operation is far from perfect, and extinguishing the nearly year-old outbreak is months away at best. Days with a dozen new cases are normal.  “Ebola is like water. If you don’t build a perfect dam, even a small hole can lead to a flood of new cases,” said Marie Roseline Belizaire, the World Health Organization’s deputy manager for the response.  Health officials are confident the outbreak is not spiraling out of control but are worri...
Read more

TDAP vaccine: When to get it, side effects, and safety

-
Image
c diff outbreak :: Article Creator Fidaxomicin Underused For C Diff Infections, Study Finds CDC / Alissa Eckert Global health organization Unitaid last week called for a "concerted global effort" to introduce accurate and affordable diagnostic tests in low-resource countries to address the rising number of gonorrhea infections and antimicrobial resistance (AMR). In a report released ahead of the United Nations High-Level Meeting on AMR, Unitaid highlights the diagnostic access gaps that results in both undertreatment and overtreatment of gonorrhea infections in low- and middle-income countries (LMICs) with a high burden of gonorrhea. Because of the lack of affordable, rapid point-of-care (POC) diagnostic tests in these settings, treatment decisions are based on observed signs and reported symptoms. Yet more than half of gonorrhea cases are asymptomatic, resulting in a high number of untreated, missed infections. Conversely, lack of gonor...
Read more

HIV Drug Sunlenca (Lenacapavir) Gets FDA Approval - Everyday Health

-
Image
The U.S. Food and Drug Administration (FDA) has approved Sunlenca (lenacapavir), a new type of medication for the most common variant of HIV, HIV-1 (human immunodeficiency virus type 1). Lenacapavir is designed for heavily treatment-experienced adults with multidrug-resistant HIV who are not able to adequately manage the virus with their current treatment regimen. It is an injectable medication administered under the skin (subcutaneously) once every six months. Developed by Gilead Sciences, lenacapavir is the first of a new class of HIV medications called capsid inhibitors, which work by blocking the virus's protein shell (the capsid), thereby interfering with essential steps of the virus's life cycle. In a clinical trial, lenacapavir was able to lower the viral load in patients who were not responding adequately to other therapies. "Today's approval ushers in a new class of antiretroviral drugs that may help patients with HIV who have run out of treatment options,...
Read more